Inhibikase Therapeutics Begins Global Phase 3 Trial of IKT-001 for Pulmonary Arterial Hypertension

Inhibikase Therapeutics has initiated patient enrollment for its global Phase 3 clinical trial, IMPROVE-PAH, which evaluates the investigational drug IKT-001 in the treatment of pulmonary arterial hypertension (PAH). The company confirmed that the first participant has been enrolled in this study, marking a significant step forward in its research efforts targeting this rare and progressive cardiovascular condition.

The Phase 3 trial aims to assess the safety and efficacy of IKT-001 as a potential therapeutic option for PAH. Pulmonary arterial hypertension is characterized by high blood pressure in the arteries connecting the heart to the lungs, often leading to severe complications such as heart failure. Inhibikase Therapeutics plans to conduct this study across multiple sites globally, with a focus on gathering comprehensive data regarding how IKT-001 impacts disease progression and patient outcomes. Further details about enrollment criteria or timelines have not yet been disclosed.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI